Cancer Res: The mechanism by which tumor-related macrophage activity is inhibited

February 13, 2021 /--- tumor cells can avoid attacks on the immune system through several mechanisms.
, for example, secrete factors that convert macrophages (cells in the immune system) into double-acting factors that promote tumor progression and protect them from the immune system.
, published in the journal Cancer Research, describes a new molecular mechanism that counteracts the immunosuppressive effects of these macrophages, which promote tumor growth.
the study was carried out by Annabel Valledor of the Department of Biology of the University of Barcelona and the Institute of Biomedical Research of the University of Barcelona.
(Photo: www.pixabay.com) macrophages are cells in the immune system that have many functions: they kill invasive pathogens, remove cells or damaged tissue, and so on.
, tumor-related macrophages can become enemies of cancer patients in tumor micro-environments.
, the field of research that has been widely promoted in the biomedical field is a discovery strategy for activating TAM and helping the immune system fight tumors and improve the effectiveness of anti-cancer treatments.
describes how the effects of a compound called TO901317 limit TAM's ability to protect tumors in experimental animals.
results, to901317 compounds inhibit the synthesis of molecules that attract regulatory T lymphocytes (Treg) to tumors.
in healthy people, Treg's most important function is to maintain a balance of the immune system and avoid harmful reactions to the body.
, however, in tumors, Treg blocks the anti-tumor activity of other types of lymphocytes.
, studies have shown that a large number of Treg tips in tumor micro-environments have poor prognosmology.
"TO901317 compound acts on the liver X-subject (LXR), a transcription factor in the nuclear-subject family that regulates gene expression and plays a key role in macrophage activity and metabolism.
as described in the article, the activation of the antagonist TO901317 on LXR inhibited the expression of the transcription factor IRF4 in macrophages.
specifically, the IRF4 factor is required, so the coercion factors Ccl17 and Ccl22 can be expressed as responses to signals such as interlethional IL-4 or GM-CSF factor.
results, the role of TO901317 compounds inhibited the production of the coercion factors Ccl17 and Ccl22, which is important for the collection of regulatory T lymphocytes into the tumor micro-environment.
once LXR is activated, the gene expression spectrum of tumor-related macrophages changes significantly, resulting in a decrease in their ability to produce immune-functioning molecules in the tumor micro environment," the study said.
(Bioon.com) Source: Researchers describe a mechanism that reseds-tumor-associated macrophage immunosupressive activity Source: Jos? M. Carbó et al. Pharmacological activation of LXR alters the expression profile of tumor-associated macrophages and the abundance of regulatory T cells in the tumor microenvironment, Cancer Research (2020). DOI: 10.1158/0008-5472.CAN-19-3360